Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05023980
Title A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN CLL-313)
Acronym BRUIN CLL-313
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Loxo Oncology, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | ROU | POL | NZL | ITA | HUN | GBR | FRA | ESP | CZE | BRA | BGR | AUT | AUS


No variant requirements are available.